Science isn’t just in petri dishes anymore. Novel technology is increasingly involved. Discoveries are being made and tested in the cloud. Artificial intelligence and machine learning algorithms are digesting data lakes and helping drive new discoveries, speed development and provide smarter care.
Scientific innovation capabilities drive the biopharma sector both to develop treatments and manage global health. But science has changed—so how we innovate must also change. The way we measure benefits for patients and populations is going to shape the future.
In 2019, Accenture identified and defined New Science: a dynamic combination of the best in science and health technology that is driving more growth than originally predicted.
New Science is Accenture’s global analysis of regulated scientific treatments in both the pipeline and the market. It classifies science using different dimensions to understand its dynamics for patients, companies and markets. The dimensions include:
Scientific novelty
Enables better understand of future areas of growth in disease and overall therapeutic areas, and better manage portfolio risk.
Unmet need
Measuring treatments that qualify as achieving current unmet need ensures development of medicines for patient impact.
Technology convergence
Measuring medicines that coexist with technology in the near-term and future ensures a better understanding of science’s growing dependence on tech.
Scott Howell, Chief Strategy Officer, US Pharmaceuticals at Novartis and Ray Pressburger, Accenture Life Sciences Commercial Services Lead, come together to discuss recent pricing, access and affordability pressures, the realities of how the industry operates today, what they think is coming next and what it will mean for patients, providers and manufacturers.
When a global pandemic forced the industry into unprecedented action, the global scientific community collaborated in exceptional ways and public-private partnerships drove innovation to address a common need with two highlights standing out: technology and science.
Technology enabled people to make the shift and work from home, care for patients at a distance, conduct clinical trials virtually and reconfigure supply chains.
Science enabled multiple COVID-19 vaccines to be developed in record time despite the remote working environment.
But, how can we use the lessons of COVID-19 to help us address system and patient-level affordability issues, while still advancing the discovery, development and delivery of new treatments for all health conditions?
Our research found three ways New Science can support and deliver the innovation that today’s economics demand.
"The investment in scientific innovation is born by all stakeholders and felt most deeply by patients. Now the goal must be maximizing return on that investment for patients, too. There are better, faster ways to deliver innovation—2020 proved that."
— STUART HENDERSON, Global Lead – Accenture Life Sciences
Find out how leaders in New Science are using digital, data and genomics to reshape the biopharma landscape and patient care.
Explore
Changing the economic relationship with customers
Ray Pressburger, Accenture Life Sciences Commercial Services Lead, looks at three ways biopharma companies can transform their economic model and their relationship with customers.
New Science: The new economics in biopharma
Elizabeth Ferguson-LaChance, Accenture Life Science Business Strategy, shares indicators of systemic change on the horizon.
New Science: Billions to millions
Petra Jantzer, Accenture Life Sciences European Union Lead, reviews the steps biopharma companies need to take to rebalance the treatment-cost equation.
